Integrity Alliance LLC. Has $3.52 Million Holdings in Amgen Inc. $AMGN

Integrity Alliance LLC. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 57.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,765 shares of the medical research company’s stock after buying an additional 3,932 shares during the quarter. Integrity Alliance LLC.’s holdings in Amgen were worth $3,524,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in shares of Amgen during the fourth quarter worth approximately $26,000. Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $336.06 on Thursday. The business’s fifty day moving average price is $343.32 and its two-hundred day moving average price is $345.27. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The stock has a market capitalization of $181.37 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 3.37 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the business posted $4.90 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts predict that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AMGN. Canaccord Genuity Group began coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective on the stock. Royal Bank Of Canada boosted their price objective on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Finally, Jefferies Financial Group initiated coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $355.19.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.